Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given
prior to meals three times a day compared to placebo (capsule that looks like active study
drug but contains no active drug), administered for 12 weeks, in diabetic subjects with
symptoms associated with gastroparesis.